GHK-Cu

GHK-Cu (glycyl-L-histidyl-L-lysine copper complex) is a naturally-occurring copper-binding tripeptide found in human plasma, saliva, and urine. The published research base concentrates heavily on topical applications: skin remodeling and cosmetic dermatology (firmness, photoaging, fine lines), wound healing in clinical contexts, hair growth (where the compound is included in some over-the-counter hair products), and burn and scar management. The systemic-supplementation literature - oral GHK-Cu or injectable GHK-Cu - is substantially smaller and more recent. Most consumer marketing for systemic use extrapolates from topical-skin and preclinical evidence.

The outcome dimensions covered most heavily in the topical literature are cosmetic skin outcomes (firmness, hydration, fine lines) and wound healing in clinical and post-surgical contexts, with hair regrowth a smaller and mostly preclinical stream. Topical GHK-Cu is included in some cosmetic and dermatologic product lines and is sold as a cosmetic ingredient, a category that needs no premarket approval in the US. The much smaller systemic-use literature covers extrapolated tendon and connective tissue applications, hair growth (oral and injectable), and broader anti-aging hypotheses, generally without the systematic-review or expert-society synthesis that would support standard consumer-supplement claims.

The defining feature of the GHK-Cu literature for systemic supplementation is the gap between topical evidence (more developed) and oral/injectable evidence (substantially smaller). Most systemic-use claims rest on extrapolation from topical and preclinical findings. Route of administration matters substantially: topical application acts locally on skin and follicle tissue, while systemic (oral or injectable) administration would have to address absorption, distribution, and metabolism in ways that the available research has not characterized in depth. Product quality and purity vary substantially across sources, particularly for injectable forms, which the FDA flagged in 2023 for immunogenicity risk when compounded.

Topical GHK-Cu is sold in cosmetic products, but published human safety data are sparse; reported topical reactions include skin irritation and redness. Systemic-supplementation safety is much less well-characterized: oral and injectable use have not been subject to the systematic safety evaluation that topical products in regulated cosmetic and pharmaceutical markets undergo. The FDA stated in 2023 that compounded injectable GHK-Cu may pose a risk of immunogenicity, with limited human data to inform safety. Excess copper intake is a theoretical concern with systemic supplementation, given the supplement delivers a copper-bound peptide and chronic high copper intake can cause adverse effects including gastrointestinal symptoms and (rarely) hepatic effects. People considering systemic (oral or injectable) GHK-Cu should be aware of the limited safety data and consult a clinician.

This summary is informational and not medical advice. Consult a clinician before starting or changing any supplement, especially if you take prescription medications.